Targeted Activation of Toll-Like Receptors: Conjugation of a Toll-Like Receptor 7 Agonist to a Monoclonal Antibody Maintains Antigen Binding and Specificity
- PMID: 26133029
- DOI: 10.1021/acs.bioconjchem.5b00302
Targeted Activation of Toll-Like Receptors: Conjugation of a Toll-Like Receptor 7 Agonist to a Monoclonal Antibody Maintains Antigen Binding and Specificity
Abstract
Therapeutic activation of Toll-like receptors (TLR) has potential for cancer immunotherapy, for augmenting the activity of antitumor monoclonal antibodies (mAbs), and for improved vaccine adjuvants. A previous attempt to specifically target TLR agonists to dendritic cells (DC) using mAbs failed because conjugation led to nonspecific binding and mAbs lost specificity. We demonstrate here for the first time the successful conjugation of a small molecule TLR7 agonist to an antitumor mAb (the anti-hCD20 rituximab) without compromising antigen specificity. The TLR7 agonist UC-1V150 was conjugated to rituximab using two conjugation methods, and yield, molecular substitution ratio, retention of TLR7 activity, and specificity of antigen binding were compared. Both conjugation methods produced rituximab-UC-1V150 conjugates with UC-1V150: rituximab ratio ranging from 1:1 to 3:1 with drug loading quantified by UV spectroscopy and drug substitution ratio verified by MALDI TOF mass spectroscopy. The yield of purified conjugates varied with conjugation method and dropped as low as 31% using a method previously described for conjugating UC-1V150 to proteins, where a bifunctional cross-linker was first reacted with rituximab and second to the TLR7 agonist. We therefore developed a direct conjugation method by producing an amine-reactive UV active version of UC-1V150, termed NHS:UC-1V150. Direct conjugation with NHS:UC-1V150 was quick and simple and gave improved conjugate yields of 65-78%. Rituximab-UC-1V150 conjugates had the expected pro-inflammatory activity in vitro (EC50 28-53 nM) with a significantly increased activity over unconjugated UC-1V150 (EC50 547 nM). Antigen binding and specificity of the rituxuimab-UC-1V150 conjugates was retained, and after incubation with human peripheral blood leukocytes, all conjugates bound strongly only to CD20-expressing B cells while no nonspecific binding to CD20-negative cells was observed. Selective targeting of Toll-like receptor activation directly within tumors or to DC is now feasible.
Similar articles
-
Immunotherapeutic activity of a conjugate of a Toll-like receptor 7 ligand.Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):3990-5. doi: 10.1073/pnas.0611624104. Epub 2007 Feb 21. Proc Natl Acad Sci U S A. 2007. PMID: 17360465 Free PMC article.
-
UC-1V150, a potent TLR7 agonist capable of activating macrophages and potentiating mAb-mediated target cell deletion.Scand J Immunol. 2018 Jun;87(6):e12666. doi: 10.1111/sji.12666. Epub 2018 May 6. Scand J Immunol. 2018. PMID: 29667229
-
Enhancement of the Immunostimulatory Activity of a TLR7 Ligand by Conjugation to Polysaccharides.Bioconjug Chem. 2015 Aug 19;26(8):1713-23. doi: 10.1021/acs.bioconjchem.5b00285. Epub 2015 Aug 5. Bioconjug Chem. 2015. PMID: 26193334
-
Antibody conjugates for targeted delivery of Toll-like receptor 9 agonist to the tumor tissue.PLoS One. 2023 Mar 13;18(3):e0282831. doi: 10.1371/journal.pone.0282831. eCollection 2023. PLoS One. 2023. PMID: 36913398 Free PMC article.
-
Modes of action of TLR7 agonists in cancer therapy.Immunotherapy. 2014;6(10):1085-95. doi: 10.2217/imt.14.75. Immunotherapy. 2014. PMID: 25428647 Review.
Cited by
-
Strategies for designing synthetic immune agonists.Immunology. 2016 Aug;148(4):315-25. doi: 10.1111/imm.12622. Epub 2016 Jul 11. Immunology. 2016. PMID: 27213842 Free PMC article. Review.
-
Antibody Conjugates for Targeted Therapy Against HIV-1 as an Emerging Tool for HIV-1 Cure.Front Immunol. 2021 Jul 1;12:708806. doi: 10.3389/fimmu.2021.708806. eCollection 2021. Front Immunol. 2021. PMID: 34276704 Free PMC article. Review.
-
In Vivo Fate of Cowpea Mosaic Virus In Situ Vaccine: Biodistribution and Clearance.ACS Nano. 2022 Nov 22;16(11):18315-18328. doi: 10.1021/acsnano.2c06143. Epub 2022 Oct 20. ACS Nano. 2022. PMID: 36264973 Free PMC article.
-
Environmentally Triggerable Retinoic Acid-Inducible Gene I Agonists Using Synthetic Polymer Overhangs.Bioconjug Chem. 2018 Mar 21;29(3):742-747. doi: 10.1021/acs.bioconjchem.7b00697. Epub 2018 Jan 19. Bioconjug Chem. 2018. PMID: 29350913 Free PMC article.
-
Exploring the next generation of antibody-drug conjugates.Nat Rev Clin Oncol. 2024 Mar;21(3):203-223. doi: 10.1038/s41571-023-00850-2. Epub 2024 Jan 8. Nat Rev Clin Oncol. 2024. PMID: 38191923 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources